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Abstract
Introduction Mechanical and morphological ischemia and re-
perfusion (I/R) injury is reduced in septic hearts. The mecha-
nism behind this Bcardioprotection^ is less well understood.
As adenosine receptors play a major role for cardioprotection
in non-septic hearts, we investigated the influence of adeno-
sine receptors in a model of I/R in septic hearts.
Methods SHAM operation or cecal ligation and puncture
(CLP) was performed in adult male Wistar rats (n = 60).
After 24 h of incubation, hearts were isolated and randomly
assigned to a group with or without adenosine receptor (Ador)
antagonists (SCH 58261 and MRS 1706) administered before
reperfusion. Ischemia and reperfusion lasted for 40 min each.
Cardiac function of the heart was determined by measuring
left ventricular pressure (LVP).
Results Before I/R, CLP hearts showed a significant mechan-
ical left ventricular impairment (CLP: 63 ± 5 mmHg vs.
SHAM: 104 ± 6 mmHg. After I/R, left ventricular function
was significantly reduced in SHAM (24 ± 32 mmHg), but
not in CLP hearts (65 ± 13 mmHg). mRNA expression for
the AdorA2a and AdorA2b was significantly increased in
CLP, but not in SHAM hearts. LVP of CLP hearts deteriorated
when AdorA2a and AdorA2b were blocked.
Conclusions The morphological and functional I/R injury in
septic animals is less pronounced compared to non-septic
animals. By a combined blockade of AdorA2a and AdorA2b
this Bcardioprotective^ effect is nearly abolished in septic
hearts. This is the first study showing, that AdorA2a and
AdorA2b may play an important role for a reduced functional
I/R injury in the septic heart.
Keywords Septic heart . Adenosine receptor . Ischemia/
reperfusion injury . AdorA2a . AdorA2b
Introduction
The new sepsis-3 definition describes sepsis as a life-
threatening organ dysfunction caused by a dysregulated host
response to infection [1]. Pro- and anti-inflammatory re-
sponses interact with hormonal, metabolic, neuronal and in
particular cardiovascular pathways. Therefore, a generalized
micro- and macrovascular dysfunction is found in sepsis
[2–4]. This may result in circulatory and cellular/metabolic
abnormalities, which may cause septic shock. Even the heart
is affected showing myocardial depression and alteration of
coronary flow [3]. As sepsis goes along with volatile hemo-
dynamics and a highly demanded heart function, an insuffi-
cient coronary blood supply to the myocardiummight be plau-
sible. This would also explain why increased cardiac bio-
markers (eg cardiac troponin I and T) are frequently found
in septic patients. However, there is general agreement that a
global ischemia is not the reason for cardiac dysfunction [3].
In fact, the underlyingmechanism behind the cardiac dysfunc-
tion in sepsis, the so-called septic cardiomyopathy, might rath-
er be multifactorial and myocardial depression factors (cyto-
kines, prostanoids, and nitric oxide, among others) and a di-
versity of activated cascades (e.g. endothelial activation, in-
duction of the coagulatory system) play prominent roles in this
context. In contrast, the changes in coronary functionmight be
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interpreted as an adaption of the heart to the elevated require-
ments in sepsis; and might bemore an advantage than a barrier
for the flow of coronary blood supply of the heart. [3–5] In this
regard, McDonough et al. showed that ischemia and reperfu-
sion injury is reduced in septic hearts [6], because 50 min of
ischemia did not affect left ventricular pressure compared to
preischemic values. These results were present at various
times of ischemic episodes in different kind of models [6–8].
However, the mechanism behind this Bcardioprotection^ is
less well understood [6].
In healthy hearts, there is substantial evidence that the pu-
rine nucleoside adenosine plays a major role in ischemia-
reperfusion (I/R) injury [9–11]. Administration of adenosine
prior to ischemia or at onset of reperfusion protects the heart
from damage. This cardioprotective effect is triggered via the
activation of membrane adenosine receptors. These receptors
are G-protein-coupled receptors, and of the existing four sub-
types (adenosine receptor: Ador; AdorA1, AdorA2a,
AdorA2b and AdorA3) all are expressed in the heart. [12]
Each of them shows cardioprotective effects, while protection
seems to be most beneficial via the activation of AdorA1 and
AdorA3 before ischemia, and the stimulation of AdorA2a,
AdorA2b during reperfusion [9, 10, 12, 13]. Administration
of selective AdorA1 receptor agonists like AMP 579 or
GR79236 before ischemia improved postischemic flow and
cardiac contractility, and reduced infarct size in both isolated
hearts and intact animals in multiple species like rat and canine
[11, 13, 14]. Stimulation of AdorA2a at the onset of reperfu-
sion leads to markedly decrease in I/R injury. For example,
Norton et al., showed a dose dependent effect of a selective
AdorA2a agonist CGS-21680 leading to a significant reduc-
tion in histologically determined infarct size [13]. The
AdorA2b as well as the AdorA3 type are both so called low-
affinity receptors. Therefore, in this case large doses of aden-
osine or analogues are necessary for a cardioprotective effect.
This might be the reason why there are conflicting results
showing that the administration of agonists (NECA and
BAY 60–6583) or even antagonists (DPCPX and BG
9928) are capable to reduce infarct size in different
models [11, 15, 16]. Lit t le is known about the
cardioprotective effect of AdorA3. There are many prob-
lems like the expression in the heart is very low, a lack of
validation, missing specific antibodies and significant spe-
cies differences in AdorA3 structure and pharmacology
[11]. A recent study by Ge et al., showed AdorA3 activa-
tion during reperfusion reduces infarct size [17]. In con-
clusion, adenosine receptors play an important role in I/R
injury in healthy hearts. The effect of adenosine receptors
in the context of sepsis with special focus on the heart and
I/R injury has not been studied so far. Therefore, the aim
of this study was to test (1) the hypothesis that septic
hearts are Bcardioprotected^ against I/R injury, and (2) if
so, whether adenosine receptors are involved.
Materials and Methods
Animals Approval from the Institutional Animal Care
Committee of the University of Regensburg, Germany (54–
2532.1-24/09) was obtained before initiation of this study.
Animal experiments have been conducted in accordance to
the German laws regulating animal care, the European
Communities Council Directive and institutional guidelines.
Experiments were conducted using adult male Wistar rats
(weighing 276 ± 55 g) purchased from Charles River
(Charles River, Sulzfeld, Germany).
Cecal Ligation and Puncture (CLP) After intraperitoneal
injection of 100 mg • kg−1 ketamine and 5 mg • kg−1 xylazine
hydrochloride, SHAM operation (only laparotomy) was car-
ried out or cecal ligation and puncture (CLP) was performed.
CLP was performed as described in detail before [18, 19].
Isolated Heart Preparations After 24 h of incubation, hearts
were isolated and the aorta was rapidly cannulated. During
preparation hearts were continuously retrogradely perfused
with a cold (6.2+/−0.2° Celsius), oxygenated, modified
Krebs-Ringer solution and transferred to a Langendorff appa-
ratus (Hugo Sachs Electronic KG, March-Hugstetten,
Germany) [18]. The modified Krebs-Ringer’s salt solution,
was filtered in-line (5 μm pore size filter disk, Sigma-
Aldrich®, Munich, Germany) and had the following compo-
sition: Na+ 140 mM; K+ 4.5 mM; Mg2+ 1.2 mM; Ca2+
2.5 mM; Cl− 134 mM; HCO3
− 15.5 mM; H2PO4
− 1.2 mM;
EDTA 0.05 mM; glucose 11.5 mM; pyruvate 2 mM; mannitol
10 mM; and insulin 5 units per liter. Krebs-Ringer solution
was equilibratedwith 95% oxygen and 5% carbon dioxide. A
fluid-filled balloon was introduced into the left ventricle.
LVEDP was kept at 0 mmHg during the stabilization period.
Hearts were perfused with a constant flow of 10 ml/min and
were paced at 350 beats/min in the ischemia and reperfusion
period. Left ventricular pressure (LVP), heartrate and coronary
flow and pressure were continuously measured, recorded dig-
itally and displayed on a screen. Throughout the experiment
all hearts were kept in a glass cage (from Hugo Sachs,
Germany) at constant temperature (36.2+/−0.6 °C).
To determine maximal coronary flow reserve, adenosine was
injected (0.2 mL of a 200 μM stock solution) directly into the
aortic root cannula during the initial control period 15 min
before and after the experiments. Post-I/R effluent was col-
lected and lactate (photometric), CK-MB and troponin I (both
luminescence oxygen channeling assay) were determined.
Protocol 1 After a stabilization period of 15 min, hearts were
randomly assigned to four experimental groups: SHAM,
SHAM + ischemia, CLP and CLP + ischemia. Each group
consisted of 5 hearts. Ischemia was induced by global
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coronary no-flow at room temperature for 40 min. After
40 min of reperfusion the hearts were weighed and were fro-
zen in liquid nitrogen (Fig. 1a).
Protocol 2 After a stabilization period of 15 min, hearts were
randomly assigned to four experimental groups: SHAM+ is-
chemia, SHAM + AdorAntagonists (SCH58261 +
MRS1706) + ischemia, CLP + ischemia, and CLP +
AdorAntagonists (SCH58261 +MRS1706) + ischemia. Each
group consisted of 10 hearts. Ischemia was induced by global
coronary no-flow and kept in a glass cage at constant temper-
ature for 40 min. Antagonists were administered with reper-
fusion. After 40 min of reperfusion the hearts were weighed
and were frozen in liquid nitrogen (Fig. 1b). A selective non-
xanthine adenosine AdorA2a antagonist SCH 58261 (Ki = 1.3
nM; Tocris bioscience, Bristol, United Kingdom) and a selec-
tive non-xanthine adenosine AdorA2b antagonist MRS1706
(Ki = 1.39 nM; Tocris bioscience, Bristol, United Kingdom) at
a concentration of 15 nM were used [20].
mRNA Extraction and Real-Time PCR Analysis Total tis-
sue and cell RNAs were extracted from homogenized tissue
with TRIzol Reagent (Invitrogen) according to the manufac-
turer’s instruction. Total RNA was reverse transcribed into
cDNA according to standard protocols as described previously
[21]. Real-time PCR for AdorA2a, AdorA2b, and β-actin was
performed in a LightCycler 480 (Roche,Mannheim, Germany).
All PCR experiments were conducted using the LightCycler
DNA Master SYBR Green I kit provided by Roche Molecular
Biochemicals (Mannheim, Germany) as described previously
[22]. The following primers were used: rat AdorA2a
(NM_053294) sense: 5′-CCGAATTCCACTCCGGTACA-3′,
antisense: 5′-CAGTTGTTCCAGCCCAGCAT-3 ′; rat
AdorA2b (NM_017161) sense: 5′-TCTTCCTCGCCTGC
TTCGT-3′, antisense: 5′-CCAGTGACCAAACCTTTATA
CCTGA-3 ′; β-actin (NM_031144) sense: 5′-CCGC
CCTAGGCACCAGGGTG-3 ′ , antisense: 5 ′-GGCT
GGGGTGTTGAAGGTCTCAAA-3′.
Protein Preparation and Immunoblotting Protein prepara-
tion and immunoblotting were performed as described previ-
ously with some minor modifications [23].
In brief, left ventricles were homogenized and lysed for
15 min in ice-cold lysis buffer (150 mM NaCl, 25 mM Tris
Fig. 1 (a) Protocol 1; (b)
protocol 2; CLP = cecal ligation
and puncture
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(pH8.0), 5 mM EDTA, 1 % Triton X-100) in the presence of a
protease inhibitor cocktail (Complete, Roche), followed by
centrifugation with 500 g for 15 min at 4 °C. The resultant
supernatant was centrifuged at 10,000 g for 30 min at 4 °C.
The resultant pellet was reconstituted in blotting buffer and
used for Western blotting.
Protein samples (20 μg) from left ventricles were electro-
phoretically separated on 10% polyacrylamide gels and trans-
ferred to nitrocellulose membranes, which were blocked over-
night in 5 % nonfat dry milk diluted in Tris-buffered saline
with 0.1 % Tween-20, and then incubated for 1 h at room
temperature with antibodies against β-Actin (ab8227,
Abcam, Cambridge, United Kingdom; 1:1000), AdorA2a
(AB1559, Merck Millipore, Billerica, MA; 1:1000) or
AdorA2b (SC28996, Santa Cruz Biotechnology, Santa Cruz,
CA; 1:1000). After being washed, the membrane was incubat-
ed for 2 h with a horseradish peroxidase–conjugated second-
ary antibody (Santa Cruz Biotechnology; 1:2000) and subject-
ed to a chemiluminescence detection system. Quantitative as-
sessment of band densities was performed densitometrically
using ImageJ Software.
Statistical Analysis All data in the text, tables and figures are
displayed asmeans ± standard error of the mean. For statistical
analysis, we applied the Kolmogorov- Smirnov test to confirm
normal distribution for each group. Raw data from each se-
lected end point were compared by unpaired Student’s t-test or
by Wilcoxon-Mann–Whitney test, respectively. P < 0.05 was
considered to be statistically significant. The statistical soft-
ware used to conduct the analyses was SPSS 16 (SPSS Inc.,
Chicago, IL, USA).
Results
First, we investigated the distribution of AdorA2a and
AdorA2b mRNA in different zones of the rat heart. We found
that AdorA2a and AdorA2b mRNA were predominantly
expressed in the right and left ventricle (Fig. 2a). Therefore,
we determined the effect of CLP on AdorA2a and AdorA2b
mRNA expression in the right and left ventricle with or with-
out ischemia (Fig. 2a). CLP for 24 h significantly increased
AdorA2a mRNA 4.1- and 2.9-fold in left and right ventricles
(p < 0.05), respectively. Ischemia and reperfusion for 40 min
each did not alter AdorA2a mRNA in SHAM- and CLP-
treated animals (Fig. 2b). CLP for 24 h also significantly in-
creased AdorA2bmRNA 9.7- and 8.5-fold in the left and right
ventricle, respectively (Fig. 2c). Ischemia and reperfusion for
40min each decreased AdorA2bmRNA to 57 and 52% in left
and right ventricles of SHAM-treated animals, respectively
(Fig. 2a). Furthermore, ischemia attenuated the CLP-induced
increase in AdorA2b mRNA in left and right ventricles to
about 52 and 58 % of values found for CLP, respectively
(Fig. 2c).
We further investigated the protein expression of AdorA2a
and AdorA2b receptors in left ventricles of rat hearts. We
found, that AdorA2a and AdorA2b protein expression signif-
icantly increased 1.43-(p < 0.05) and 1.59-fold (p < 0.05), re-
spectively, in CLP-treated animals compared to SHAM-
treated animals (Fig. 3).
Baseline values for left ventricular pressure before I/R for
SHAM and SHAM +MRS1706 + SCH58261, CLP, and
CLP +MRS1706 + SCH58261 were 104 ± 6 mmHg, 97 ±
2 mmHg, 63 ± 5 mmHg and 70 ± 2 mmHg, respectively.
Before I/R CLP hearts showed a significant mechanical left
ventricular impairment compared to SHAM hearts (Fig. 4).
Fig. 2 (a) AdorA2a and AdorA2b mRNA expression in the left atrium
(LA), right atrium (RA), right ventricle (RV), and left ventricle (LV) in
SHAM animals. *p < 0.05 ventricle vs. atrium. (b) AdorA2a mRNA
expression in the right (RV) and left ventricle (LV) in sham- or CLP-
treated animal with or without ischemia (I). (c) AdorA2b mRNA
expression in the right (RV) and left ventricle (LV) in sham- or CLP-
treated animal with or without ischemia (I). Data are means ± SEM of 5
animals per group. *p < 0.05 vs. sham-treated animals without ischemia
(I)
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After I/R, a significant LVP reduction was measured in
SHAM hearts (24 ± 32 mmHg); CLP hearts LVP remained
nearly unchanged (65 ± 13mmHg) compared to pre-ischemia.
Administration of SCH58261 and MRS1706 at reperfusion
markedly reduced LVP in the CLP group, and almost dimin-
ished the Bcardioprotective^ effect in septic hearts. In the
SHAM + SCH58261 + MRS1706 group, the combined
blockade of AdorA2a and AdorA2b led to an electromechan-
ical dissociation (pressureless electrical activity) in 8 of 10
hearts (80 %). An electromechanical dissociation was seen
in SHAM and CLP in 40 and 20 %, respectively.
Baseline values for coronary flow before I/R for SHAM,
SHAM + SCH58261 + MRS1706, CLP, and CLP +
SCH58261 + MRS1706 were 11.5 ± 0.7 ml/min, 11.1 ±
0.4 ml/min, 11.4 ± 0.4 ml/min, 11.2 ± 0.8 ml/min, respective-
ly. Before I/R, maximal coronary flow responses to bolus
adenosine administration were significantly increased in all
groups compared to baseline values (Fig. 5). After I/R an
adenosine reaction was only seen in both CLP groups, not in
the other groups. Besides the functional results, we collected
cardiac enzymes in the effluent after I/R. Cardiac proteins, like
troponin I (TNI), were significantly lower in CLP compared to
SHAM. A combined blockade of AdorA2a and AdorA2b in
CLP hearts led to significantly increase of lactate, CK-MB,
and TNI (p < 0.05) (Fig. 6).
Discussion
The results of the presented study show a reduced morpholog-
ical and functional damage after ischemia and reperfusion in
an isolated septic rat heart model. The maintenance of left
ventricular function after a prolonged I/R episode was accom-
panied by a less pronounced release of cardiac enzyme, tro-
ponin I, as indirect measurement of the integrity of the cell.
Furthermore, we were able to demonstrate a markedly in-
crease of mRNA and protein expression of AdorA2a and
AdorA2b in ventricles of septic hearts. By blocking
AdorA2a and AdorA2b at the onset of reperfusion the


































Fig. 3 Relative Optical Density (OD) from immunoblots of AdorA2a
and AdorA2b of left ventricular tissue 24 h after CLP. Values are given as
fold of sham-treated animals. Values are related to signals that were
obtained for β-actin. Data are means ± SEM of 3 animals per group.
*p < 0.05 vs. sham-treated animals
Fig. 4 Pre- and post-I/R left




*p < 0.05 SHAM vs. CLP and
CLP + SCH58261 +MRS1706;
#p < 0.05 SHAM+ SCH58261 +
MRS1706 vs. CLP and CLP +
SCH58261 +MRS1706. Post-I/R
vs. Pre-I/R: §p < 0.05 for CLP +
SCH58261 +MRS1706,
$p < 0.05 for SHAM and
&p < 0.05 for SHAM+
SCH58261 +MRS1706. The data
are presented as the means ± SEM
of 10 animals per group
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Therefore, it seems that Ador plays an important role in the
cardioprotection of septic hearts.
In healthy hearts, it is well known that the activation of
adenosine receptors play a major role for cardioprotection
[9–11]. However, little is known about this mechanism of I/
R injury in non-healthy hearts, especially in septic hearts. This
is of prominent interest as sepsis goes along with a variety of a
variable hemodynamic with long and lasting episodes of hy-
potension, a dysfunction of the microvascular bed and the
administration of vasoactive drugs [2, 3]. All of these may
compromise the coronary integrity that may lead to ischemia
and exposing the septic hearts to increased risk.
However, it seems that in sepsis hearts are cardioprotected.
McDonough et al. were one of the first showing a reduced I/R
injury, after a short and even a long term ischemic episode in
septic hearts [6, 8]. After ischemia septic hearts showmechan-
ical and morphological reperfusion injury to a lesser extent
than sham hearts [6, 7]. These results concur with ours.
After I/R left ventricular function was reduced is SHAM
hearts, but not in CLP hearts. Adding Ador-Antagonists at
reperfusion abolished the cardioprotection of CLP hearts.
There is growing evidence that adenosine receptor may
play a major role for cardioprotection in cardiovascular dis-
ease, eg in diabetes [24]. For example, A3 receptor might be a
possible cardioprotectant in diabetes, which is currently under
extensive investigation [24]. Therefore we investigated if
adenosine receptors may play a role for the cardioprotection
seen in septic hearts. We showed an increased expression of
mRNA and protein for AdorA2a and AdorA2b in the septic
hearts. A combined blockade of these receptors led to a sig-
nificant decrease in the left ventricular function after I/R in
these hearts. This could be interpreted that the activation of
both receptors (AdorA2a and AdorA2b) are necessary for the
cardioprotection of the septic heart. This hypothesis is sup-
ported by a recent study from Xi and colleagues [20]. They
reported that AdorA2a and AdorA2b need to work in concert
to produce a strong and consistent protection against reperfu-
sion injury in rat hearts. Furthermore, Zhan et al. showed
recently, that both AdorA2a and AdorA2b are required for
adenosine A1 receptor-mediated cardioprotection, which im-
plicated an interaction among the receptor subtypes [12].
Recently, McIntosh and Lasley pointed out that for the
Fig. 5 Increase of coronary flow
(CF) after administration of
adenosine before and after I/R.
*p < 0.05 before I/R and #p < 0.05
after I/R for baseline vs. SHAM,
SHAM+ SCH58261 +
MRS1706, CLP, or CLP+
SCH58261 +MRS1706. The data
are presented as the means ± SEM
of 10 animals per group
Fig. 6 Lactate, CK-MB, and TNI
in post-I/R effluat of SHAM,
CLP, and CLP + SCH58261 +
MRS1706. * and #p < 0.05
SHAM and CLP vs. CLP +
SCH58261 +MRS1706,
respectively. $p < 0.05 SHAM vs.
CLP. The data are presented as the
means ± SEM of 10 animals per
group
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cardioprotection there is significant evidence that all 4 sub-
types are important [11].
Studies in healthy animals have shown that the activation
of AdorA2a prior to ischemia does not result in a reduction of
myocardial I/R injury [11]. However, stimulation of AdorA2a
at the onset of reperfusion leads to markedly decrease in I/R
injury. For example, Norton et al., showed a dose dependent
effect of a selective AdorA2a agonist CGS-21680 leading to a
significant reduction in histologically determined infarct size
[13]. In addition, other studies in a similar model showed, that
the application of antagonists (SCH58261 or MRS1706) at
reperfusion reverses the infarct size reducing effects of
AdorA2 agonists [20]. We administered the antagonists at
reperfusion, which led to a decreased left ventricular function
and a pronounced release of cardiac enzyme as indirect mea-
surement of cellular destruction in the Bonce protected^ septic
heart. This assumes that Bcardioprotection^ in septic hearts is
probably generated at the phase of reperfusion. However, oth-
er pathways or mechanism (eg MAPK-dependent mecha-
nism) might also be important for the Bcardioprotection^ in
septic hearts [25].
Clinical studies of septic patients showed an alternated cor-
onary function with a high coronary blood flow and a dimin-
ished coronary artery-coronary sinus oxygen difference [26].
Based on these findings and a generalized vascular dysfunc-
tion in mind, a disturbed coronary flow autoregulation has
been speculated [3]. Our Langendorff apparatus, is a well
recognized model that allows examination of direct coronary
vascular effects independent of autoregulation [27, 28].
Therefore, as sepsis-induced alteration of coronary flow be-
fore I/R can be ruled out in this model. Furthermore, only CLP
hearts exhibited sufficient coronary reserve after I/R, which
indicates that coronary autoregulatory capability was only in-
tact in CLP and not in the other groups. Consequently, the up-
regulation of adenosine receptors may have led to the mainte-
nance of coronary autoregulation in CLP, and I/R may have
triggered the excessive effect. This may be the mechanism
behind the cardioprotection seen in septic hearts.
Furthermore, based on other studies metabolic effects, like
level of high energy phosphate, amount of anaerobic glycol-
ysis or myocardial catalase levels are less likely to be the
reason for cardioprotection [6, 8].
We do understand well that this study has limitations.
Although the applied sepsis model has several advantages
(e.g. ‘natural’ course of infection, closely mimicing human dis-
ease by activating pro- and anti-inflammatory pathways), there
are some limitations, especially with regard to noteworthy out-
come variability [29, 30]. In contrast, bolus injection-sepsis
models indeed offer a simple and highly standardized method,
but it has been shown that they do not reflect all aspects of the
sepsis syndrome [29, 30]. However, as other studies using a
different sepsis model showed comparable results, the model
per se might not have been a limitation [6, 8].
Furthermore, we did not apply different Ador-antagonists.
We concentrated on SCH58261 and MRS1706. We chose
these antagonists as they are more selective for AdorA2a
(100-323-fold) and AdorA2b (113-165-fold) than for
AdorA1 or AdorA3, respectively [20]. However, we can not
rule out that an activation or blockade of AdorA1 and/or
AdorA3 might have influenced our results and conclusion.
Furthermore, other possible causes for the cardioprotection
in sepsis, eg up-regulation of iNOS were not part of our in-
vestigation, and their relevance might be underestimated [3].
Conclusion The morphological and functional I/R injury in
septic animals is less pronounced compared to healthy hearts.
By application of combined AdorA2a + b antagonists this
Bcardioprotective^ effect is reduced in septic hearts. Our re-
sults suggest for the first time that septic hearts are more or
less cardioprotected, the adenosine receptors AdorA2a and
AdorA2b play predominant role for a reduced morphological
and functional I/R injury in the septic heart. It is plausible that
an intact coronary autoregulation play the most important role
for the cardioprotection seen in septic hearts.
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